Zimmer Biomet (NYSE:ZBH) Hits New 12-Month Low - Should You Sell?

Key Points

• Shares hit a new 52-week low, trading as low as $81.35 amid heavy volume, with the selloff linked to headlines about a CFO departure and reports of a CEO exit that amplified investor uncertainty despite the earnings release.
• Strong Q1 results and raised guidance: adjusted EPS of $2.09 beat the $1.86 estimate, revenue was $2.09 billion (up ~9.3% YoY), and management raised FY-2026 adjusted EPS guidance to $8.40–$8.55.
• Analyst and ownership backdrop: ratings are mixed (one Strong Buy, seven Buys, 12 Holds, three Sells) with a MarketBeat consensus "Hold" and an average target of $105.95, while institutional investors own about 88.9% of the shares.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $81.35 and last traded at $82.9540, with a volume of 9823679 shares changing hands. The stock had previously closed at $92.59.

Zimmer Biomet News Summary

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q1 results beat expectations — adjusted EPS $2.09 vs. $1.86 estimate and revenue $2.09B, with reported sales up ~9.3% year-over-year and margin expansion, showing underlying business strength. Zimmer Biomet Announces First Quarter 2026 Financial Results
• Positive Sentiment: Company raised FY-2026 adjusted EPS guidance to $8.40–$8.55 (slightly above consensus) and reiterated revenue targets, supporting forward earnings outlook. Medical device maker Zimmer Biomet raises annual profit forecast, announces CFO departure
• Neutral Sentiment: Analyst write-ups highlight strong segment growth, solid organic sales and improved key metrics, but note mixed pre-market reaction (shares dipped despite the beat), indicating some investor profit-taking or concern about near-term execution. ZBH Q1 Earnings & Revenues Top Estimates, Stock Dips in Pre-Market
• Negative Sentiment: Chief Financial Officer Suketu Upadhyay departed effective April 28; an interim CFO was named. Management turnover in the finance role is creating uncertainty and likely weighing on the stock. Zimmer Biomet Announces Chief Financial Officer Transition
• Negative Sentiment: Reports of a CEO exit were published alongside the earnings release; headlines about executive departures and the company’s underperformance versus peers amplified investor concern and contributed to the selloff. Zimmer Biomet falls after CEO exit, unchanged growth outlook

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ZBH. TD Cowen upgraded shares of Zimmer Biomet from a "hold" rating to a "buy" rating in a research report on Monday, January 26th. Barclays cut their target price on shares of Zimmer Biomet from $104.00 to $100.00 and set an "underweight" rating for the company in a research report on Thursday, February 12th. William Blair started coverage on shares of Zimmer Biomet in a research report on Friday, February 20th. They issued a "market perform" rating for the company. Leerink Partners started coverage on shares of Zimmer Biomet in a research report on Monday, April 13th. They issued a "hold" rating and a $101.00 price target for the company. Finally, Weiss Ratings upgraded shares of Zimmer Biomet from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Tuesday, April 7th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $105.95.

Zimmer Biomet Price Performance

The firm's fifty day moving average price is $93.23 and its 200 day moving average price is $92.89. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. The stock has a market cap of $16.06 billion, a PE ratio of 23.43, a P/E/G ratio of 1.89 and a beta of 0.61.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The firm had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.06 billion. During the same quarter in the previous year, the firm earned $1.81 earnings per share. The company's quarterly revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.39 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 annualized dividend and a yield of 1.2%. Zimmer Biomet's dividend payout ratio (DPR) is 27.12%.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the transaction, the senior vice president owned 10,224 shares in the company, valued at $967,803.84. This trade represents a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.28% of the stock is owned by company insiders.

Hedge Funds Weigh In On Zimmer Biomet

Several institutional investors have recently bought and sold shares of ZBH. Brighton Jones LLC bought a new position in Zimmer Biomet during the fourth quarter valued at $204,000. Sivia Capital Partners LLC bought a new position in Zimmer Biomet during the second quarter valued at $232,000. United Bank lifted its position in Zimmer Biomet by 10.7% during the second quarter. United Bank now owns 11,896 shares of the medical equipment provider's stock valued at $1,085,000 after purchasing an additional 1,153 shares during the last quarter. Federated Hermes Inc. lifted its position in Zimmer Biomet by 129.2% during the second quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider's stock valued at $194,000 after purchasing an additional 1,202 shares during the last quarter. Finally, Cerity Partners LLC lifted its position in Zimmer Biomet by 93.6% during the second quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider's stock valued at $7,004,000 after purchasing an additional 37,116 shares during the last quarter. Institutional investors own 88.89% of the company's stock.

About Zimmer Biomet

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.